Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410703 | 0.86 | FFAR4 (0.47) | DPP4FFAR4NOTUMMEN1KMT2A | |
| SCHEMBL12809867 | 0.80 | DPP4 (0.46) | DPP4FFAR4NOTUMMAPTRBP4 | |
| SCHEMBL1409379 | 0.79 | FFAR4 (0.49) | DPP4FFAR4NOTUM | |
| SCHEMBL1410200 | 0.72 | DPP4 (0.45) | DPP4FFAR4NOTUMRBP4ACACB | |
| SCHEMBL1410170 | 0.70 | DPP4 (0.47) | DPP4KHKFFAR4NOTUMRBP4 | |
| SCHEMBL29141963 | 0.69 | ACACB (0.47) | DPP4FFAR4NOTUMACACB | |
| SCHEMBL1409875 | 0.69 | FFAR4 (0.54) | DPP4KHKFFAR4NOTUMRBP4 | |
| SCHEMBL1410617 | 0.68 | NOTUM (0.63) | NOTUMMAPTACACBMEN1KMT2A | |
| SCHEMBL1410206 | 0.67 | FFAR4 (0.65) | DPP4KHKFFAR4NOTUMRBP4 | |
| SCHEMBL25228830 | 0.67 | TSHR (0.48) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | DPP4 1356/4885KHK 2373/4885FFAR4 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.